| As the population ages, the incidence of osteoporosis gradually increases, of which postmenopausal osteoporosis (PMOP) accounts for a very large proportion. Moreover, osteoporosis is not easy to identify, and it often develops into a fracture before it is detected, and this brings a great deal of trouble to the daily life of postmenopausal women. However, its pathogenesis is still unclear. Therefore, actively exploring its pathogenesis factors and mechanism has become an urgent problem to be solved. With the deepening of exploration in recent years, the disorder of lipid metabolism has become one of the hot spots for studying the pathogenesis of PMOP. The incidence rate of abnormal lipid metabolism and osteoporosis in women has increased after menopause. In addition, drugs used to treat both of them have also been found to have common benefits, which opens up a new therapeutic approach for the treatment of PMOP. In many studies of lipid metabolism, low density lipoprotein (LDL) has been found to be related to PMOP, and the increase in low density lipoprotein may be a risk factor for postmenopausal osteoporosis. This article summarizes the reports of postmenopausal low-density lipoprotein levels, the role of low-density lipoproteins in bone metabolism, and the effects of lipid-lowering drugs on PMOP, in order to lay a foundation for further study on the relationship between LDL and PMOP. |